Dr. Suvà is working to better understand and treat the aggressive brain cancer glioblastoma multiforme (GBM). Researchers in his laboratory have recently found that GBM cells can exist in one of four biochemically distinct cellular states and that the ratio of cells in these states can vary in tumors. They are now working to characterize the genetics and tumor microenvironments that lead to each state, determine the relationship and transitions between them, and identify drugs that can best target each one. Dr. Suvà is an Assistant Professor in the Department of Pathology at Massachusetts General Hospital and an Institute Member at the Broad Institute of MIT and Harvard. His expertise is in neuro-oncology and in single-cell genomic technologies. He obtained his MD and PhD in Lausanne, Switzerland.
PUBLISHED RESEARCH
Suvà ML, Tirosh I. The Glioma Stem Cell Model in the Era of Single-Cell Genomics. Cancer Cell. 2020.
Hara T, Chanoch-Myers R, Mathewson ND, Myskiw C, Atta L, Bussema L, Eichhorn SW, Greenwald AC, Kinker GS, Rodman C, Gonzalez Castro LN, Wakimoto H, Rozenblatt-Rosen O, Zhuang X, Fan J, Hunter T, Verma IM, Wucherpfennig KW, Regev A, Suvà ML, Tirosh I. Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma. Cancer Cell. 2021.
Gonzalez Castro LN, Tirosh I, Suvà ML. Decoding Cancer Biology One Cell at a Time. Cancer Discov. 2021.
Chaligne R , Gaiti F, Silverbush D, Schiffman JS, Weisman HR, Kluegel L, Gritsch S, Deochand SD, Gonzalez Castro LN, Richman AR, Klughammer J , Biancalani T, Muus C, Sheridan C, Alonso A, Izzo F , Park J, Rozenblatt-Rosen O, Regev A, Suvà ML, Landau DA. Epigenetic encoding, heritability and plasticity of glioma transcriptional cell states. Nat Genet. 2021.
Datta M, Chatterjee S, Perez EM, Gritsch S, Roberge S, Duquette M, Chen IX, Naxerova K, Kumar AS, Ghosh M, Emblem KE, Ng MR, Ho WW, Kumar P, Krishnan S, Dong X, Speranza MC, Neagu MR, Iorgulescu JB, Huang RY, Youssef G, Reardon DA, Sharpe AH, Freeman GJ, Suvà ML, Xu L, Jain RK. Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models. Proc Natl Acad Sci U S A. 2023.
Spitzer A, Gritsch S, Nomura M, Jucht A, Fortin J, Raviram R, Weisman HR, Gonzalez Castro LN, Druck N, Chanoch-Myers R, Lee JJY, Mylvaganam R, Lee Servis R, Fung JM, Lee CK, Nagashima H, Miller JJ, Arrillaga-Romany I, Louis DN, Wakimoto H, Pisano W, Wen PY, Mak TW, Sanson M, Touat M, Landau DA, Ligon KL, Cahill DP, Suvà ML, Tirosh I. Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma. Cancer Cell. 2024.